Adimmune (TPE:4142) Beneish M-Score: -2.67 (As of Jun. 26, 2026)


TPE:4142 Adimmune Corp TPE:4142
55 GF Score
Price NT$16.80
GF Value NT$25.40
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Adimmune Beneish M-Score?

Adimmune TPE:4142 -1.75% 55 Beneish M-Score is -2.67 as of Jun. 26, 2026. GuruFocus rates TPE:4142 with a GF Score™ of 55/100 and a GF Value™ of NT$25.40 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 831 Biotechnology companies, Adimmune ranks better than 63.78% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.67 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Adimmune's Beneish M-Score or its related term are showing as below:

TPE:4142' s Beneish M-Score Range Over the Past 10 Years
Min: -4.19   Med: -2.5   Max: 6.58
Current: -2.67

During the past 13 years, the highest Beneish M-Score of Adimmune was 6.58. The lowest was -4.19. And the median was -2.50.


Adimmune Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Adimmune's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adimmune Beneish M-Score Chart

Adimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.32 0.90 -0.35 -3.95 -2.67

Adimmune Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.95 -3.07 -2.94 1.55 -2.67

TPE:4142 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Adimmune's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adimmune Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adimmune's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Adimmune's Beneish M-Score falls into.


TPE:4142
55GF Score
Adimmune Corp TPE:4142
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adimmune Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Adimmune for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8688+0.528 * 1.398+0.404 * 0.891+0.892 * 0.9001+0.115 * 1.0527
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9137+4.679 * -0.028616-0.327 * 1.1135
=-2.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$147 Mil.
Revenue was 745.462 + 475.322 + 108.613 + 72.104 = NT$1,402 Mil.
Gross Profit was 369.463 + 84.407 + -44.099 + -121.284 = NT$288 Mil.
Total Current Assets was NT$3,271 Mil.
Total Assets was NT$8,193 Mil.
Property, Plant and Equipment(Net PPE) was NT$4,015 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$215 Mil.
Selling, General, & Admin. Expense(SGA) was NT$374 Mil.
Total Current Liabilities was NT$1,546 Mil.
Long-Term Debt & Capital Lease Obligation was NT$1,594 Mil.
Net Income was 220.418 + -18.257 + -218.797 + -223.253 = NT$-240 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0 Mil.
Cash Flow from Operations was 826.953 + -355.082 + -265.399 + -211.918 = NT$-5 Mil.
Total Receivables was NT$188 Mil.
Revenue was 545.069 + 888.242 + 79.8 + 43.878 = NT$1,557 Mil.
Gross Profit was 113.1 + 440.273 + -34.999 + -70.313 = NT$448 Mil.
Total Current Assets was NT$3,610 Mil.
Total Assets was NT$8,481 Mil.
Property, Plant and Equipment(Net PPE) was NT$3,818 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$216 Mil.
Selling, General, & Admin. Expense(SGA) was NT$455 Mil.
Total Current Liabilities was NT$1,161 Mil.
Long-Term Debt & Capital Lease Obligation was NT$1,758 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(146.864 / 1401.501) / (187.806 / 1556.989)
=0.104791 / 0.120621
=0.8688

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(448.061 / 1556.989) / (288.487 / 1401.501)
=0.287774 / 0.205841
=1.398

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3271.118 + 4014.536) / 8192.632) / (1 - (3610.004 + 3817.653) / 8481.453)
=0.110707 / 0.124247
=0.891

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1401.501 / 1556.989
=0.9001

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(215.698 / (215.698 + 3817.653)) / (214.863 / (214.863 + 4014.536))
=0.053479 / 0.050802
=1.0527

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(374.283 / 1401.501) / (455.107 / 1556.989)
=0.267059 / 0.292299
=0.9137

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1593.825 + 1545.848) / 8192.632) / ((1757.614 + 1161.31) / 8481.453)
=0.383231 / 0.344154
=1.1135

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-239.889 - 0 - -5.446) / 8192.632
=-0.028616

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Adimmune has a M-score of -2.67 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.67 mean?
Adimmune (TPE:4142) has a Beneish M-Score of -2.67 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Adimmune and its competitors. According to the industry distribution chart, Adimmune ranks #301 out of 831 companies in the Biotechnology industry, placing it in the top 36.2%.
Is Adimmune's Beneish M-Score too high?
Adimmune's current Beneish M-Score is -2.67. Based on the distribution chart, Adimmune ranks #301 out of 831 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Adimmune has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adimmune's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Adimmune ranks #301 out of 831 companies for Beneish M-Score. This puts Adimmune in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Adimmune and its competitors. Adimmune's current Beneish M-Score is -2.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adimmune stock overvalued right now?
Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Possible Value Trap. The stock's GF Value™ is NT$25.40, compared to a current price of NT$16.80 — trading 33.9% below its estimated fair value. The current Beneish M-Score is -2.67. Adimmune's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Adimmune (TPE:4142), the current Beneish M-Score is -2.67 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adimmune (TPE:4142) Overvalued in 2026?

Based on GuruFocus' analysis, Adimmune stock appears to be undervalued. The current stock price of NT$16.80 is trading 33.9% below its estimated GF Value™ of NT$25.40. GuruFocus considers Adimmune to be Possible Value Trap.

Key valuation signals for TPE:4142:

  • Beneish M-Score: -2.67
  • GF Value™: NT$25.40 vs. price of NT$16.80 (33.9% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Adimmune Business Description

Address Tanxing Road, No. 3, Section 1, Tanzi District, Taichung City, TWN, 427003
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
55GF Score

Get the complete analysis for TPE:4142

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.80
Price
NT$25.40
GF Value